Yabing Mai

Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma

Joaquim Bellmunt, Ronald de Wit, David J. Vaughn et al. · New England Journal of Medicine · 2017 · 3.4K citations · Full text

Medicine, Oncology, Pharmacology +17

Health-Related Quality-of-Life Analysis From KEYNOTE-045: A Phase III Study of Pembrolizumab Versus Chemotherapy for Previously Treated Advanced Urothelial Cancer

David J. Vaughn, Joaquim Bellmunt, Yves Fradet et al. · Journal of Clinical Oncology · 2018 · 121 citations

Medicine, Oncology, Pharmacotherapy +11

A Meta-analysis to Assess the FDA DAVP’s TLOVR Algorithm in HIV Submissions

F. M. Smith, Thomas Hammerstrom, Greg Soon et al. · Drug Information Journal · 2011 · 57 citations

Public Health, Biostatistics, Good Clinical Practice +7

Effect of angiotensin receptor blockade on insulin sensitivity and endothelial function in abdominally obese hypertensive patients with impaired fasting glucose

Todd S. Perlstein, Robert R. Henry, Kieren J. Mather et al. · Clinical Science · 2011 · 29 citations

Medicine, Endocrinology, Pharmacology +17

Planned survival analysis from KEYNOTE-045: Phase 3, open-label study of pembrolizumab (pembro) versus paclitaxel, docetaxel, or vinflunine in recurrent, advanced urothelial cancer (UC).

Dean F. Bajorin, Ronald de Wit, David J. Vaughn et al. · Journal of Clinical Oncology · 2017 · 22 citations

Medicine, Pharmacology, Chemotherapy +11